ARIX BIOSCIENCE HAS MADE $25 MILLION COMMITMENT TO LEADING THERAPEUTICS RESEARCH ACCELERATOR, BIOMOTIV

18th April 2016

LONDON, APRIL 18, 2016: –

Arix Bioscience Limited (Arix Bioscience), formerly Perceptive Bioscience Investments Limited, a global healthcare and life science company supporting medical innovation, announced today it has agreed to provide up to $25 million capital to BioMotiv LLC, a US-based therapeutic accelerator organisation providing access to pioneering science in leading universities.

Arix Bioscience sources, finances and develops businesses addressing medical innovation at all stages of development. Arix Bioscience and BioMotiv have formed a strategic investment partnership that will enable wide-ranging support for innovative university-sourced projects and discoveries.

BioMotiv is the for-profit collaborator of The Harrington Project for Discovery & Development, based at University Hospitals in Cleveland, Ohio. The Harrington Project is a $250 million initiative with an aim of identifying, funding, and rapidly advancing the development of medical breakthroughs, primarily in the US.

Arix Bioscience has agreed to provide BioMotiv with capital of $25 million. BioMotiv‘s current portfolio includes seven project companies in development. Two of these project companies, Dual Therapeutics and Orca Pharmaceuticals, have partnership arrangements in place with leading Pharmaceutical companies.

As part of the strategic partnership, Arix Bioscience will have an opportunity to co-invest and spin-out project companies from BioMotiv and will nominate a member of its management team to serve as a member of the BioMotiv Advisory Board which oversees the screening and selection of projects.

To date, the Harrington Project has reviewed over 1,500 opportunities from over 110 US and UK institutions and selected more than 50 opportunities for support.

Arix Bioscience was founded by leading figures in the international healthcare and life science sectors; Dr Joe Anderson, Chief Executive Officer (formerly a partner with Abingworth LLP), Jonathan Peacock, Chairman (formerly CFO of Amgen and Novartis Pharma) and Professor Sir Christopher Evans, OBE, Deputy Chairman (one of Europe’s world class entrepreneurs). The company commenced operations with initial funding led by Woodford Investment Management and other institutional investors.

Dr Joe Anderson, Chief Executive Officer of Arix Bioscience, said: “We are delighted to have formed this strategic partnership with BioMotiv and it demonstrates our support for medical innovation at all stages of development. We are pleased to be joining eminent research and investment organisations such as Biogen,Takeda and Charles River Laboratories within BioMotiv. Our corporate strategy is structured in such a way that we are unconstrained by geography or stage of company development. With start up companies, outstanding opportunities are to be found around the world and we are pleased to have already secured relationships with science-based universities in the UK, EU and Australia as well as in the US through BioMotiv and a network of leading academic centres and companies.”

Baiju R. Shah, Chief Executive Officer of BioMotiv, said: “We are very pleased to partner with Arix Bioscience given its renowned leadership team, unique platform, and passion for innovation. Through the partnership, BioMotiv and its companies can leverage Arix’s expertise, networks, and financial support to more rapidly and successfully accelerate breakthrough discoveries into medicines.”